Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. MEDIFAST INC

42.6% sales growth and 75.43% return on equity

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific.

MEDIFAST INC’s sales growth this year is expected to be 28.8% and 19.5% for next year.

Year-on-year quarterly revenue growth grew by 42.8%, now sitting on 840.56M for the twelve trailing months.

MEDIFAST INC’s sales growth for the next quarter is 42.6%. The company’s growth estimates for the current quarter and the next is 43.4% and 37.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 75.43%.

Volatility

MEDIFAST INC’s last day, last week, and last month’s average volatility was a positive 0.28%, a negative 0.31%, and a negative 0.34%, respectively.

MEDIFAST INC’s last day, last week, and last month’s high and low average amplitude percentage was 4.10%, 3.87%, and 3.50%, respectively.

MEDIFAST INC’s Stock Yearly Top and Bottom Value

MEDIFAST INC’s stock is valued at $195.41 at 16:22 EST, under its 52-week high of $208.57 and way higher than its 52-week low of $49.03.

MEDIFAST INC’s Moving Average

MEDIFAST INC’s worth is higher than its 50-day moving average of $191.37 and way higher than its 200-day moving average of $166.33.

2. Niu Technologies

138.2% sales growth and 20.55% return on equity

Niu Technologies designs, manufactures, and sells smart electric-scooters in the People's Republic of China.

Niu Technologies’s sales growth this year is expected to be 22.9% and 75.5% for next year.

Year-on-year quarterly revenue growth grew by 36.7%, now sitting on N/A for the twelve trailing months.

Niu Technologies’s sales growth for the next quarter is 138.2%. The company’s growth estimates for the ongoing quarter and the next is a negative 38.5% and 250%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.55%.

Volatility

Niu Technologies’s last day, last week, and last month’s average volatility was a positive 2.57%, a positive 0.33%, and a negative 0.13%, respectively.

Niu Technologies’s last day, last week, and last month’s high and low average amplitude percentage was 7.30%, 5.12%, and 5.82%, respectively.

Niu Technologies’s Stock Yearly Top and Bottom Value

Niu Technologies’s stock is valued at $28.79 at 16:22 EST, way under its 52-week high of $37.44 and way above its 52-week low of $6.08.

Niu Technologies’s Moving Average

Niu Technologies’s value is below its 50-day moving average of $29.97 and way above its 200-day moving average of $24.08.

3. Genmab A/S

50.6% sales growth and 36.46% return on equity

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark.

Genmab A/S’s sales growth this year is anticipated to be 102.3% and a negative 20.4% for next year.

Year-on-year quarterly revenue growth grew by 65.8%, now sitting on N/A for the twelve trailing months.

Genmab A/S’s sales growth for the next quarter is 50.6%. The company’s growth estimates for the present quarter and the next is a negative 64.5% and 30%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 36.46%.

Volatility

Genmab A/S’s last day, last week, and last month’s average volatility was a negative 0.25%, a positive 0.80%, and a positive 0.30%, respectively.

Genmab A/S’s last day, last week, and last month’s high and low average amplitude percentage was 2.90%, 1.65%, and 1.57%, respectively.

Genmab A/S’s Stock Yearly Top and Bottom Value

Genmab A/S’s stock is valued at $40.66 at 16:22 EST, below its 52-week high of $41.50 and way higher than its 52-week low of $16.24.

Genmab A/S’s Moving Average

Genmab A/S’s worth is higher than its 50-day moving average of $38.30 and way higher than its 200-day moving average of $36.49.

4. Analog Devices, Inc.

15.7% sales growth and 10.3% return on equity

Analog Devices, Inc. designs, manufactures, and markets integrated circuits (ICs), algorithms, software, and subsystems that leverage analog, mixed-signal, and digital signal processing technologies.

Analog Devices, Inc.’s sales growth this year is anticipated to be 11.5% and 7% for next year.

Year-on-year quarterly revenue growth grew by 5.8%, now sitting on 5.6B for the twelve trailing months.

Analog Devices, Inc.’s sales growth for the next quarter is 15.7%. The company’s growth estimates for the present quarter and the next is 27.2% and 26.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.3%.

Volatility

Analog Devices, Inc.’s last day, last week, and last month’s average volatility was 1.06%, 0.62%, and 0.23%, respectively.

Analog Devices, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 1.44%, 1.56%, and 1.75%, respectively.

Analog Devices, Inc.’s Stock Yearly Top and Bottom Value

Analog Devices, Inc.’s stock is valued at $147.73 at 16:22 EST, under its 52-week high of $147.83 and way higher than its 52-week low of $79.08.

Analog Devices, Inc.’s Moving Average

Analog Devices, Inc.’s worth is above its 50-day moving average of $140.58 and way higher than its 200-day moving average of $124.33.

5. Allegiance Bancshares, Inc.

27.3% sales growth and 5.97% return on equity

Allegiance Bancshares, Inc. operates as the bank holding company for Allegiance Bank that provides a range of commercial banking services primarily to small and medium-sized businesses, professionals, and individual customers.

Allegiance Bancshares, Inc.’s sales growth this year is expected to be 9.3% and 1.6% for next year.

Year-on-year quarterly revenue growth grew by 16.1%, now sitting on 177.9M for the twelve trailing months.

Allegiance Bancshares, Inc.’s sales growth for the next quarter is 27.3%. The company’s growth estimates for the ongoing quarter and the next is 6% and 411.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.97%.

Volatility

Allegiance Bancshares, Inc.’s last day, last week, and last month’s average volatility was 1.07%, 0.25%, and 0.22%, respectively.

Allegiance Bancshares, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 2.32%, 2.78%, and 3.06%, respectively.

Allegiance Bancshares, Inc.’s Stock Yearly Top and Bottom Value

Allegiance Bancshares, Inc.’s stock is valued at $34.13 at 16:22 EST, way under its 52-week high of $38.95 and way higher than its 52-week low of $20.88.

Allegiance Bancshares, Inc.’s Moving Average

Allegiance Bancshares, Inc.’s worth is higher than its 50-day moving average of $33.30 and way higher than its 200-day moving average of $27.19.

6. Gilead Sciences, Inc.

7.3% sales growth and 6.46% return on equity

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally.

Gilead Sciences, Inc.’s sales growth this year is expected to be 5.3% and a negative 0.3% for next year.

Year-on-year quarterly revenue growth grew by 17.4%, now sitting on 23.15B for the twelve trailing months.

Gilead Sciences, Inc.’s sales growth for the next quarter is 7.3%. The company’s growth estimates for the ongoing quarter and the next is 31.5% and 1.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.46%.

Volatility

Gilead Sciences, Inc.’s last day, last week, and last month’s average volatility was a positive 2.84%, a positive 0.31%, and a negative 0.23%, respectively.

Gilead Sciences, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.18%, 1.70%, and 1.53%, respectively.

Gilead Sciences, Inc.’s Stock Yearly Top and Bottom Value

Gilead Sciences, Inc.’s stock is valued at $58.26 at 16:22 EST, way below its 52-week high of $85.97 and higher than its 52-week low of $56.56.

Gilead Sciences, Inc.’s Moving Average

Gilead Sciences, Inc.’s value is below its 50-day moving average of $59.66 and way below its 200-day moving average of $65.73.

LEAVE A REPLY

Please enter your comment!
Please enter your name here